Testosterone induced priapism in Kallmann's syndrome.
I. Shergill,N. Pranesh,R. Hamid,M. Arya,I. Anjum
DOI: https://doi.org/10.1097/01.JU.0000049199.37765.C9
2003-03-01
Abstract:Kallmann’s syndrome, a congenital form of hypogonadotropic hypogonadism, can be managed with a short course of intramuscular testosterone injections, with the aim of inducing puberty. Recognized complications of this treatment include gynecomastia, fusion of bone epiphyses resulting in short stature and hypercalcemia. Testosterone therapy is also associated with increased frequency and duration of erection but reported cases of priapism are extremely rare.1 We report a case of testosterone induced priapism and discuss the possible pathogenesis of this rare but important complication. CASE REPORT An 18-year-old white male with delayed onset of secondary sexual characteristics was diagnosed with Kallmann’s syndrome. Testosterone level was 1 nmol./l. (normal 10 to 35), follicle-stimulating hormone less than 0.2 units per l. (1 to 8) and luteinizing hormone less than 0.2 units per l. (3 to 8). History was remarkable for bilateral inguinal orchiopexy at age 6 years for undescended testes. A short course of intramuscular testosterone injections was elected. Ten days after the first injection of 100 mg. testosterone esters (Sustanon, Organon, Ess, The Netherlands), the patient presented with painful priapism. There was no history of perineal trauma, malignancy, sickle cell anemia or use of other medications. Aspiration of the corpora cavernosa revealed dark blood with pH less than 7.21, partial oxygen pressure 28 mm. Hg and partial carbon dioxide pressure 65 mm. Hg, confirming low flow priapism. Although the immediate response was favorable, priapism recurred within 24 hours. A cavernous spongiosal shunt (Winter shunt) was then performed and the tumescence subsided. DISCUSSION The most common pharmaceutical agents causing priapism include intracavernous and oral treatments for erectile dysfunction, psychotropic drugs, arterial vasodilators and -blockers. Surprisingly testosterone associated priapism is extremely rare.1 Circulating testosterone levels normally have a diurnal variation in young men, usually reaching a mean maximum of 25 nmol./l. at approximately 8:00 a.m. and decreasing to a mean minimum of 15 nmol./l. at approximately 10:00 p.m. Intramuscular administration of testosterone leads to a supraphysiological increase in total serum testosterone, with peak levels (70 nmol./l.) being achieved within 48 hours and a return to baseline occurring at approximately 21 days. Therefore, there is a significant period during which high levels of circulating testosterone are present. Considering the temporal relationship and the absence of any known etiological factor, priapism in this case was almost certainly caused by intramuscular testosterone administration. Although the exact pathogenesis of testosterone induced priapism is not clear, several mechanisms are possible. Specifically in patients with Kallmann’s syndrome priapism may occur following sudden exposure to testosterone after a period of prolonged deprivation. Also, it has been shown that supraphysiological levels of testosterone may predispose men to polycythemia and subsequent thrombosis as a result of stimulation of erythropoiesis.2 A known risk factor for low flow priapism, polycythemia was excluded in this case by a normal hematocrit. Mills et al demonstrated in a rat model that blood flow to the cavernous sinuses was under testosterone control and probably mediated by nitric oxide.3 Although not confirmed in humans, an increase in local testosterone levels, as occurs with intramuscular administration, may result in an increased susceptibility to priapism.